SCHEMBL5865005

SCHEMBL5865005

[O-][n+]1ccccc1C=Cc1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.64
MEN1 O00255 2/20 0.64
NPC1 O15118 2/20 0.64
KMT2A Q03164 2/20 0.64
NFE2L2 Q16236 7/20 0.53
ACHE P22303 2/20 0.46
PABPC1 P11940 1/20 0.43
EIF4H Q15056 1/20 0.43
APP P05067 1/20 0.39
PTGS1 P23219 1/20 0.39
FBP1 P09467 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
STAT3 P40763 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864999 1.00 RAB9A (0.64) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL4712807 0.85 RAB9A (0.67) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL4712805 0.85 RAB9A (0.67) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL5865378 0.82 RAB9A (0.69) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL5865373 0.82 RAB9A (0.69) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL5864837 0.82 RAB9A (0.64) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL5864841 0.82 RAB9A (0.64) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL5864976 0.81 NFE2L2 (0.58) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL5864970 0.81 NFE2L2 (0.58) RAB9AMEN1NPC1KMT2ANFE2L2
SCHEMBL5865302 0.78 NPC1 (0.63) RAB9AMEN1NPC1KMT2ANFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1837195-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2006-09-27 CN disclosed
US-7034044-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2006-04-25 US disclosed
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER 2006-03-16 US disclosed
US-6951875-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
CN-1578662-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2005-02-09 CN disclosed
EP-1443926-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-11 EP disclosed
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER (FR) 2004-04-08 US disclosed
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. 2003-07-31 US disclosed
WO-2003037333-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C RAB9A 2741/4885MEN1 2517/4885NPC1 646/4885
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C RAB9A 2741/4885MEN1 2517/4885NPC1 646/4885
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN3A, GRIN2C RAB9A 2959/4885MEN1 2586/4885NPC1 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.